Sequana statistics

To access cutting-edge analytics on consensus tools, life science contexts and associated fields, you will need to subscribe to our premium service.


Citations per year

Citations chart

Popular tool citations

chevron_left Libraries/frameworks chevron_right
Popular tools chart

Tool usage distribution map

Tool usage distribution map

Associated diseases

Associated diseases

Sequana specifications


Unique identifier OMICS_19255
Name Sequana
Alternative name Sequanix
Software type Pipeline/Workflow
Interface Command line interface, Graphical user interface
Restrictions to use None
Operating system Unix/Linux, Mac OS
Programming languages Python
License BSD 3-clause “New” or “Revised” License
Computer skills Advanced
Version 0.6.4
Stability Stable
Registration required No
Maintained Yes


  • Sequanix



Add your version



  • person_outline Dimitri Desvillechabrol <>
  • person_outline Thomas Cokelaer <>

Additional information

Publications for Sequana

Sequana in publications

PMCID: 5906171
PMID: 29059456
DOI: 10.1002/hep.29607

[…] consults for and is employed by sanyal bio. he consults for pfizer, nimbus, nitto denko, hemoshear, and lilly. he received grants from conatus, novartis, galectin, bristol‐myers squibb, merck, and sequana. he received royalties from elsevier and uptodate. he owns stock in akarna, genfit, and newco. dr. anstee consults for intercept, abbott, inventiva, acclaim, pfizer, falk, eli lilly, genfit, […]

PMCID: 5716582
PMID: 29206839
DOI: 10.1371/journal.pone.0188151

[…] interests: rajiv jalan has research collaborations with ocera and yaqrit, consults for ocera and yaqrit and has received speaking fees from sequana. rajiv jalan is the founder of yaqrit limited, which is developing ucl inventions for treatment of patients with cirrhosis. this does not alter our adherence to plos one policies on sharing […]

PMCID: 5767767
PMID: 28802062
DOI: 10.1002/hep.29466

[…] owns stock in hemoshear. he consults and advises pfizer, boehringer ingelheim, nimbus, nitto denko, lilly, and ardelyx. he received grants from novartis, galectin, bristol‐myers squibb, merck, and sequana. he is employed by sanyal bio. he received royalties from elsevier and uptodate. he owns stock in exhalenz, akarna, genfit, durect, and indalo., supported by intercept pharmaceuticals, gilead […]

PMCID: 5698811
PMID: 28940225
DOI: 10.1111/apt.14331

[…] is a frequent complication of cirrhosis, requiring large volume paracentesis or placement of a transjugular intrahepatic portosystemic shunt (tipss). the automated low‐flow ascites pump (alfapump, sequana medical ag, zurich, switzerland) is an innovative treatment option for patients with ra., to assess safety and efficacy of this treatment in patients with a contraindication to tipss., […]

PMCID: 5431836
PMID: 28500294
DOI: 10.1038/s41598-017-01709-0

[…] the manuscript for important intellectual content, obtained funding and study supervision., pere ginès declares that he has received research funding from ferring pharmaceuticals, grifols s.a., and sequana medical. he has participated on advisory boards for noorik, ikaria, ferring pharmaceuticals, promethera and sequana medical. all other authors declare that they have no competing […]

To access a full list of publications, you will need to upgrade to our premium service.

Sequana institution(s)
Institut Pasteur - Pole Biomics - Paris, France; Institut Pasteur - Bioinformatics and Biostatistics Hub - C3BI, USR 3756 IP CNRS - Paris, France
Sequana funding source(s)
Supported by France Génomique consortium ANR10-INBS-09-08.

Sequana reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review Sequana